Seed targeting with tiny anti-miR-155 inhibits malignant progression of multiple myeloma cells

Journal of Drug Targeting

Volumn 23, Issue 1, 2015, Pages 59-66

  Feng, Maoxiao ^a   Luo, Xiaochuang ^a   Gu, Chunming ^a   Fei, Jia ^a  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

miR 155; Multiple myeloma; Seed targeting; Tiny anti miRNA

Indexed keywords

CD19 ANTIGEN; MICRORNA 155; SUPPRESSOR OF CYTOKINE SIGNALING 1; ANTISENSE OLIGONUCLEOTIDE; MICRORNA; MIRN155 MICRORNA, HUMAN; SOCS1 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL COUNT; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; MYELOMA CELL; SIGNAL TRANSDUCTION; TUMOR GENE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL MIGRATION ASSAY; CELL SURVIVAL; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MIGRATION ASSAYS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MULTIPLE MYELOMA; OLIGONUCLEOTIDES, ANTISENSE; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR STEM CELL ASSAY;

EID: 84919883702     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2014.951653     Document Type: Article

References (44)

1. Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet 2009;374:324-39.
2. Benetatos L, Vartholomatos G. Deregulated microRNAs in multiple myeloma. Cancer 2012;118:878-87.
3. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364:1046-60.
4. Di Martino MT, Gullà A, Cantafio ME, et al. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 2013;4:242-55.
5. Tassone P, Tagliaferri P, Rossi M, et al. Genetics and molecular profling of multiple myeloma: novel tools for clinical management? Eur J Cancer 2006;42:1530-8.
6. Dimopoulos K, Gimsing P, Grønbæk K. Aberrant microRNA expression in multiple myeloma. Eur J Haematol 2013;91:95-105.
7. Lionetti M, Agnelli L, Lombardi L, et al. MicroRNAs in the pathobiology of multiple myeloma. Curr Cancer Drug Targets 2009;12:823-37.
8. Di Martino MT, Leone E, Amodio N, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012;18:6260-70.
9. Bakkus M, Dujardin S, Van Riet I, De Waele M. MicroRNA expression analysis in multiple myeloma plasma cells and cell lines by a quantitative real-time PCR approach. Blood 2007;110:729A [Abstract 2472].
10. Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008;105:12885-90.
11. Lionetti M, Biasiolo M, Agnelli L, et al. Identification of microRNA expression patterns and definition of a microRNA/ mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009;114:e20-6.
12. Ameres, SL, Martinez, J, Schroeder, R. Molecular basis for target RNA recognition and cleavage by human RISC. Cell 2007;130: 101-12.
13. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003;425:415-19.
14. Obad S, dos Santos CO, Petri A, et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 2011;43:371-8.
15. Tam W. Identification and characterization of human BIC, a gene on chromosome 21 that encodes a non-coding RNA. Gene 2001;274:157-67.
16. Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005;102:3627-32.
17. Saito Y, Suzuki H, Tsugawa H, et al. Overexpression of miR-142-5p and miR-155 in gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to Helicobacter pylori eradication. PLoS One 2012;7:e47396.
18. Zang YS, Zhong YF, Fang Z, Li B, An J. MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression. Cancer Gene Ther 2012;19:773-8.
19. Higgs G, Slack F. The multiple roles of microRNA-155 in oncogenesis. J Clin Bioinforma 2013;3:17. doi: 10.1186/2043-9113-3-17.
20. Rodriguez A, Vigorito E, Clare S, et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007;316:608-11.
21. Roccaro AM, Sacco A, Chen C, et al. microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia. Blood 2009;113:4391-402.
22. Zheng SR, Guo GL, Zhai Q, et al. Effects of miR-155 antisense oligonucleotide on breast carcinoma cell line MDA-MB-157 and implanted tumors. Asian Pac J Cancer Prev 2013;14:2361-6.
23. Haas KM, Tedder TF. Role of the CD19 and CD21/35 receptor complex in innate immunity, host defense and autoimmunity. Adv Exp Med Biol 2005;560:125-39.
24. Tedder TF, Isaacs CM. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes: a new member of the immunoglobulin superfamily. J Immunol 1989;143:712-17.
25. Fujimoto M, Poe JC, Jansen PJ, et al. CD19 amplifies B lymphocyte signal regulates Src-family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 2000;13:47-57.
26. Rickert RC, Rajewsky K, Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995;376:352-5.
27. Sato S, Steeber DA, Tedder TF. The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation. Proc Natl Acad Sci USA 1995;92:11558-62.
28. Cannizzo E, Carulli G, Del Vecchio L, et al. The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model. Am J Clin Pathol 2012;137:377-86.
29. Mahmoud MS, Fujii R, Ishikawa H, Kawano MM. Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity. Blood 1999;94:3551-8.
30. Mateo G, Montalbán MA, Vidriales MB, et al.; PETHEMA Study Group; GEM Study Group. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with highdose therapy. J Clin Oncol 2008;26:2737-44.
31. Jeong TD, Park CJ, Shim H, et al. Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells. Korean J Hematol 2012;47:260-6.
32. Yao R, Ma YL, Liang W, et al. MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1. PLoS One 2012;7:e46082.
33. Davey GM, Heath WR, Starr R. SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation. Tissue Antigens 2006;67:1-9.
34. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009;15:425-30.
35. O'Connell RM, Taganov KD, Boldin MP, et al. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 2007;104:1604-9.
36. Kutty RK, Nagineni CN, Samuel W, et al. Inflammatory cytokines regulate microRNA-155 expression in human retinal pigment epithelial cells by activating JAK/STAT pathway. Biochem Biophys Res Commun 2010;402:390-5.
37. Jiang S, Zhang HW, Lu MH, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010;70:3119-27.
38. Rai D, Kim SW, McKeller MR, et al. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci USA 2010;107:3111-16.
39. Leaman D, Chen PY, Fak J, et al. Antisense-mediated depletion reveals essential and specific functions of microRNAs in Drosophila development. Cell 2005;121:1097-108.
40. Davis S, Lollo B, Freier S, Esau C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 2006;34:2294-304.
41. Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3:87-98.
42. Li Y, Zhu X, Gu J, et al. Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis. Hematology 2010;15:215-21.
43. Esau CC. Inhibition of microRNA with antisense oligonucleotides. Methods 2008;44:55-60.
44. Broderick JA, Zamore PD. MicroRNA therapeutics. Gene Ther 2011;18:1104-10.